Sponsored

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

A manuscript that wil  certainly be discussed in lung MDT! The thought of a  RCT in these earlier stages may be already in the mind of the sponsors… The authors do not report synergic side effects so far.

0 comments

Leave a Reply

Log In

New to CTSNet? Sign Up